December 21, 2018
ObsEva in third phase testing looks at long term administration of linzagolix
ObsEva is evaluating long term administration of linzagolix in two dosing regimens with recruited patients for third phase of testing oral gonadotropin releasing hormone (GnRH) receptor antagonist Linzagolix.